Virtual Library
Start Your Search
Jill Feldman
Author of
-
+
GS02 - Prevention, Early Detection and Patient Provider Partnerships (ID 8)
- Event: NACLC 2019
- Type: Invited Speaker Session
- Track:
- Presentations: 1
- Moderators:
- Coordinates: 10/11/2019, 08:05 - 09:45, Imperial Ballroom (B2 Level)
-
+
GS02.06 - How Lung Cancer Advocacy and Research Has Changed in the Past Years (ID 154)
08:05 - 09:45 | Presenting Author(s): Jill Feldman, Jill Feldman
- Abstract
Abstract not provided
-
+
OA03 - IO Concerns and Targeted Therapies (ID 3)
- Event: NACLC 2019
- Type: Oral Abstract Session
- Track:
- Presentations: 1
- Moderators:
- Coordinates: 10/12/2019, 09:45 - 11:15, Rouge (Lobby Level)
-
+
OA03.06 - Impact of an EGFR-lung Cancer Diagnosis on Quality of Life of Patients: Learnings from Project PRIORITY (ID 108)
09:45 - 11:15 | Presenting Author(s): Jill Feldman
- Abstract
Background:
EGFR-positive lung cancer comprises 10%-35% of adenocarcinoma diagnoses. However, the impact of an EGFR-positive diagnosis on patient quality of life has not been well documented.
Method:
Project PRIORITY, a patient-founded and patient-driven IRB-approved study, aims to understand unmet needs of the global EGFR-positive lung cancer community. A comprehensive patient-facing semi-structured survey about the diagnostic and treatment journey of patients, with a focus on quality of life, was developed with input from expert clinicians and pilot-tested among English-speaking patients both locally and internationally. Quality-of-life measures included hospitalization and side-effect burden, mental health, and access to therapies for managing their cancer.
Results:
Some of the major findings from the 280 patients and caregivers (on behalf of their patients) who responded to the survey are noted below: 1) About 63% had undergone hospitalization for a procedure related to their lung cancer (49%), due to a symptom related to lung cancer (38%) or due to a side effect of the lung cancer treatment (22%). Of those who underwent hospitalization, the mean number of hospitalization and mean number of days spent in the hospital were 2.08 times and 10.55 days, respectively. The most common severe side effects associated with increased hospitalization were diarrhea and nausea, even among those patients receiving tyrosine kinase inhibitors (TKIs). 2) Around 1-in-4 respondents reported being diagnosed with depression by their healthcare provider; half of them developed depression following their lung cancer diagnosis. However, only 35% of participants diagnosed with depression participated in a lung cancer support group (online or in-person). 3) Sixty-nine percent of respondents reported that cost of therapy to self was a major financial concern of receiving treatment. Sub-group analysis of US and non-US respondents revealed that 65% of non-US patients reported availability of the right treatment in their country to be an important component of access to a specific medication, compared to 48% of US respondents (p<0.01). Additional analysis of how clinical characteristics of the disease intersect with quality of life is ongoing.
Conclusion:
Even in the era of TKIs, a diagnosis of EGFR-positive lung cancer can significantly impair the quality of life of patients, as measured by healthcare utilization and psychosocial burden of the disease. Management of EGFR-positive lung cancer should encompass strategies that address both physical and mental health components of the illness as well as issues related to drug access.
